

Index

ABBREVIATED NEW DRUG APPLICATION (ANDA)

Generally, **25:1 to 25:61**
Approval date, redating, infringement damages and remedies, **32:3 to 32:5**
Approval matrix, **25:23**
Attorney involvement in answering deficiency letters, **25:26**
Based on confidential information protective order, prohibited uses, **34:8**
Bioavailability
generally, **25:13**
defined, **25:28**
Bioequivalency of generic drug
definition of bioequivalency, **25:29**
differences between NDA and ANDA, **25:8**
dissolution testing, **25:39, 25:40**
immediate and extended release forms, **25:30, 25:31**
in vitro bioequivalency testing, reasons for BE testing and biowaivers, **25:41**
in vitro dissolution studies, **25:38**
non-obviousness of failed biostudies as evidence, **25:37**
particle size and dissolution testing, **25:40**
proving bioequivalency, **25:37 to 5:40**
showing bioequivalency of generic versions, **25:27**
standardized testing protocols, **25:39**

ABBREVIATED NEW DRUG APPLICATION (ANDA)

—Cont'd

Bioequivalency of generic drug
—Cont'd
traditional solid oral dosage forms, **25:30, 25:60**
Biopharmaceutical properties, classification system
generally, **25:14**
pharmacokinetics, patents claiming, **25:15**
Biopharmaceutical review and bioavailability, **25:13**
Biostudies in human subjects
generally, **25:42**
fasting and fed biostudies, **25:43**
food effect patents not patentable, **25:44**
pilot and pivotal studies, **25:42**
Brand side exclusivities, when to file ANDAs with paragraph IV certifications, **23:7**
CGMP review, **25:18**
Changes to application
generally, **25:52**
major changes, **25:53**
minimal impact change
documented in annual report, **25:55**
minor change, **25:55**
moderate changes (CBE-30), **25:54**
patent issues, **25:56**
Chemistry and manufacturing controls (CMC), **25:12**
Citizen petition denial and ANDA approvals, implications of, **34:5**

**ABBREVIATED NEW DRUG
APPLICATION (ANDA)**

—Cont'd

Clinical review, **25:17**
 Color of generic products, issues relating to, **25:61**
 Commercial issues in the Rx to OTC switch, **37:5**
 Competitive generic therapies, FDA waiting 75 days, **30:6**
 Considerations for 180-day exclusivity in Rx to OTC switch, **37:6**
 Contrasts and similarities with paper NDAs, **24:2, 24:3**
 Deficiency letters
 generally, **25:19**
 attorney involvement in answering, **25:26**
 major deficiency, **25:20**
 minor deficiency, **25:21**
 telephone amendment, **25:22**
 Designing around RLD patents to obtain non-infringing generic versions, **25:58**
 Differences between NDA and ANDA, **24:6**
 Dose inhalers, metered and powder, **25:48**
 Dry powder nose inhalers, **25:49**
 Excipient changes
 generally, **25:58, 25:59**
 non-solid oral dosage forms, **25:59**
 Extended release
 diffusion control system, **25:32, 25:33**
 dissolution control system, **25:34**
 ion-exchange resin system, **25:36**
 measuring bioequivalence, **25:30, 25:31**
 osmotic pump system, **25:35**
 types of ER, **25:32 to 25:36**

**ABBREVIATED NEW DRUG
APPLICATION (ANDA)**

—Cont'd

Filing against OTC NDA drug product, **37:3**
 Final vs. tentative approval, **25:24**
 Forfeiture
 failure to obtain tentative approval in 30 months, forfeiture of 180-day exclusivity. **Paragraph IV Based 180-Day Exclusivity** (this index)
 FDA backlog possibly causing forfeitures, **29:28**
 filing ANDA too early, **29:34**
 Human subjects. Biostudies in human subjects, above
 Impurity
 avoiding impurity patent claims, risk of jeopardizing regulatory approval, **25:47**
 levels as defined by regulatory authority, **25:46**
 specifications, **25:45**
 Inhalers
 dry powder nose inhalers, **25:49**
 metered and powder dose inhalers, **25:48**
 nasal sprays and inhaled solutions, **25:50**
 Inner workings of FDA, **25:10**
 In vitro
 bioequivalency testing, reasons for BE testing and biowaivers, **25:41**
 dissolution studies, **25:38**
 Labels
 labeling review, **25:11**
 last minute RLD label changes to thwart generic competition, **25:7**
 Last minute RLD label changes to thwart generic competition, **25:7**

INDEX

ABBREVIATED NEW DRUG APPLICATION (ANDA)

—Cont'd

- Literal infringement
 - current ANDA infringement for future modifications, **16:8**
 - infringement inquiry, ANDA specification controls, **16:7**
- Major changes to application, **25:53**
- Metered and powder dose inhalers, **25:48**
- Microbiology review, **25:16**
- Minimal impact change documented in annual report, **25:55**
- Minor change to application, **25:55**
- Moderate changes (CBE-30), **25:54**
- Nasal sprays and inhaled solutions, **25:50**
- Orange Book Patent Certifications** (this index)
- Paper NDAs, contrasts and similarities, **24:2, 24:3**
- Pediatric exclusivities, effect on ANDA filings, **23:19**
- Petitions, suitability, to refer to different RLDs, **25:2**
- Pharmacokinetics, patents claiming, **25:15**
- Redating approval date, infringement remedies, **32:3 to 32:5**
- Reference listed drug (RLD)
 - generally, **25:1**
 - access to RLD protected by REMS, **25:9**
 - designing around RLD patents to obtain non-infringing generic versions, **25:58**
 - last minute RLD label changes to thwart generic competition, **25:7**
 - suitability petitions to refer to different RLDs, **25:2**

ABBREVIATED NEW DRUG APPLICATION (ANDA)

—Cont'd

- Refusal to receive (RTR)
 - ANDA filing date, effect of refusal to receive, **25:60**
 - challenging RTR decision, **25:5**
 - impact of, **25:4**
 - no private right of action to enforce FDCA, **25:5**
- Review of ANDA approval process, **25:57**
- Samples, patent issues, **25:51**
- Size, shape and color of generic products, issues relating to, **25:61**
- Submission filing date, **25:60**
- Submission standards, **25:4**
- Telephone amendment, minor deficiency, **25:22**
- Tentative approval
 - failure to obtain in 30 months, forfeiture of 180-day exclusivity. **Paragraph IV Based 180-Day Exclusivity** (this index)
 - final vs. tentative approval, **25:24**
 - reasons for getting, **25:25**

AFFIDAVITS

- Inequitable Conduct** (this index)

ANTICIPATION

- Novelty and Loss of Rights** (this index)

ATTORNEYS' FEES

- Amounts, **32:36**
- Case studies, **32:37, 32:38**
- Exceptional cases
 - generally, **32:32 to 32:38**
 - amounts, **32:36**
 - case studies, **32:37, 32:38**
 - frivolous litigation by brand company, **32:38**
 - prevailing party, who is, **32:35**

ATTORNEYS' FEES—Cont'd

- Exceptional cases—Cont'd
 - steps in awarding, **32:34**
 - when fees can be awarded, **32:33**
- Frivolous litigation by brand company, **32:38**
- Inequitable conduct, award of fees and costs, **19:6**
- Prevailing party, who is, **32:35**
- Steps in awarding, **32:34**
- When fees can be awarded, **32:33**

BASICS

- Patent Basics** (this index)

BEST MODE (§ 112)

- Generally, **8:1 to 8:7**
- Best mode in claim construction, **8:7**
- Contrasting enablement and best mode, **9:13**
- Inequitable conduct, using to challenge best mode violations when invalidity not allowed, **8:6**
- Invalidity based on best mode no longer allowed under AIA, **8:5**
- Patent invalidity theories, best mode requirement, **8:4**
- Role of specification, **8:1**
- Section 112(a) (pre-AIA § 112, first paragraph)
 - generally, **8:2**
 - best mode requirement, **8:3**

BIOEQUIVALENCY

- Abbreviated New Drug Application (ANDA)** (this index)

BRAND DRUG APPROVAL AND ORANGE BOOK

- Generally, **22:1 to 22:22**
- Antibiotic patents, **22:17**
- Approval and approval dates, **22:23**

BRAND DRUG APPROVAL AND ORANGE BOOK—Cont'd

- Blinds. Clinical trials and blinds, below
- Brand drug approval, generally, **22:2**
- Clinical trials and blinds
 - generally, **22:19**
 - beginning clinical trials, **22:3**
 - phases of trials, **22:20, 22:21**
 - public use patent invalidity, **22:21**
- Drug master files (DMF), **22:6**
- Internal FDA machinations, **22:8**
- Investigational new drug application (IND)
 - generally, **22:3**
 - beginning clinical trials, **22:3**
 - contents, **22:4**
- Listable and nonlistable patents
 - generally, **22:10**
 - delisting patents, **22:12**
 - forcible listing of unlisted patents, **22:14**
 - listing as clerical not substantive, **22:11**
 - polymorph patent listing, **22:18**
 - when patents may be listed, **22:15**
 - who may list which patents, **22:16**
- Medical device patents, **22:17**
- New drug applications (NDA)
 - generally, **22:5**
 - approval and approval dates, **22:23**
 - differences between NDA and ANDA, **25:6**
 - drug master files (DMF), **22:6**
 - paper NDAs and § 505(b)(2) applications, below
 - types of new drugs, **22:7**
- Orange Book, patent information and
 - generally, **22:9 to 22:13**

INDEX

BRAND DRUG APPROVAL AND ORANGE BOOK—Cont'd

- Orange Book, patent information and—Cont'd
 - clerical, not substantive, nature of patent listing, **22:11**
 - delisting patents, **22:12**
 - forcible listing of unlisted patents, **22:14**
 - listable and nonlistable patents, **22:10**
 - when patents may be listed, **22:15**
 - who may list which patents, **22:16**
- Paper NDAs and § 505(b)(2) applications
 - generally, **22:22**; **24:1 to 24:9**
 - challenge to § 505(b)(2) reference listed drug, **24:8**
 - circumventing 180-day exclusivity, **24:7**
 - conclusion, **24:9**
 - contrasting with abbreviated (ANDA) applications, **24:2**
 - information need to support application, **24:5**
 - reference listed drug, challenge to, **24:8**
 - similarities with abbreviated (ANDA) applications, **24:3**
 - strategic uses, **24:6, 24:7**
 - types of applications, **24:4**
- Polymorph patent listing, **22:18**
- Public use patent invalidity, **22:21**
- REMS patents, **22:17**
- Types of new drugs in NDA, **22:7**

BRAND SIDE EXCLUSIVITIES

- Generally, **23:1 to 23:27**
- ANDAs with paragraph IV certifications, when to file, **23:7**
- Approval, **23:1**
- Clinical information. New product/clinical information/

BRAND SIDE EXCLUSIVITIES —Cont'd

- supplemental exclusivity, below
- Combination products
 - generally, **23:4**
 - pediatric exclusivity, **23:25**
- DEA scheduling, NCE exclusivity and, **23:3**
- Delisting patents from Orange Book before NCE-1 date to thwart generic filings, **23:9**
- Enantiomers, three-year exclusivity, **23:14**
- Extension of five-year exclusivity under qualified infectious disease products program, **23:5**
- Extensions of 30-month stay to year 7.5, NCE-based lawsuits, **23:8, 27:26**
- Filing, **23:1**
- Fixed combination products, **23:4**
- Generic approval of less than all indications, working example, **23:12**
- Infringement implications, **23:26**
- New chemical entity (NCE) exclusivity
 - generally, **23:2**
 - DEA scheduling, **23:3**
 - delisting patents from Orange Book before NCE-1 date to thwart generic filings, **23:9**
 - difference between NCE and three-year exclusivity, **23:13**
 - extension of five-year exclusivity under qualified infectious disease products program, **23:5**
 - extensions of 30-month stay to year 7.5, NCE-based lawsuits, **23:8, 27:26**
 - fixed combination products, **23:4**

BRAND SIDE EXCLUSIVITIES

—Cont'd

- New chemical entity (NCE) exclusivity—Cont'd
 - new molecules, NCE status vs. patent term extension, **23:6**
 - when to file ANDAs with paragraph IV certifications, **23:7**
- New molecules, NCE status vs. patent term extension, **23:6**
- New product/clinical information/supplemental exclusivity
 - generally, **23:10**
 - difference between NCE and three-year exclusivity, **23:13**
 - generic approval of less than all indications, working example, **23:12**
 - new clinical information exclusivity, requirements, **23:11**
- Orphan drug exclusivity, **23:15**
- Patent infringement implications, **23:26**
- Pediatric exclusivity
 - generally, **23:16 to 23:25**
 - ANDA filings, effect on, **23:19**
 - combination products, **23:25**
 - effect, **23:17**
 - key points, **23:27**
 - monetary damages not permitted, **32:24**
 - paragraph IV based 180-day exclusivity, **28:19**
 - thirty-month stay, effect on
 - generally, **23:20**
 - amlodipine, **23:24**
 - fentanyl patch, **23:23**
 - fluconazole, **23:22**
 - working examples, **23:21 to 23:24**
 - tracking, **23:18**

BRAND SIDE EXCLUSIVITIES

—Cont'd

- Qualified infectious disease products program, extension of five-year exclusivity, **23:5**
- Supplemental exclusivity. New product/clinical information/supplemental exclusivity, above

CERTIFICATIONS

- Orange Book Patent Certifications** (this index)

CHEMICALS

- New chemical entity (NCE). **Brand Side Exclusivities** (this index)
- Similarity. **Obviousness** (this index)

CITIZEN PETITIONS

- Generally, **34:1 to 34:7**
- Based on confidential information from ANDA; protective order prohibited uses, **34:8**
- FDA response
 - time period, **34:3**
 - what is, **34:4**
- Form of petition, **34:2**
- Generic companies, **34:7**
- Implications of petition denial and ANDA approvals, **34:6**
- Sham petitions, potential antitrust penalties, **34:5**
- Tentative approval, failure to obtain in 30 months, forfeiture of 180-day exclusivity, **29:26**
- What is, **34:1**

CLAIM CONSTRUCTION IN PATENT INFRINGEMENT

- Generally, **15:1 to 15:30**
- Basic infringement claim, **15:2**
- Chemical compounds, enantiomers and racemates, **15:28**

INDEX

CLAIM CONSTRUCTION IN PATENT INFRINGEMENT —Cont'd

- Claim construction, generally, **15:3**
- Consistent use of claim term throughout specification, **15:11**
- Customary rules of construction, **15:8**
- Dictionaries as sources of claim meaning, **15:7**
- Differentiation of claims and interpreting claims of different scope, **15:24**
- Embodiment is invention, **15:13**
- Evidence considered
 - generally, **15:4**
 - dictionaries, **15:7**
 - extrinsic evidence, **15:6**
 - intrinsic evidence, **15:5**
 - mandatory evidence, **15:5**
 - permissive evidence, **15:6**
 - treatises, **15:7**
- Explicit disclaimer of definition in specification, **15:15**
- Extrinsic evidence, **15:6**
- Implicit definition of claim term, consistent use throughout specification, **15:11**
- Implicit disclaimer of definition in specification, **15:17**
- Inexact modifiers, **15:25**
- Inter partes review (IPR), using, **15:19.50**
- Intrinsic evidence
 - generally, **15:5**
 - prosecution history, **15:19**
- Limiting claim scope, consistent with invention's purpose, **15:16**
- Mandatory evidence, **15:5, 15:19**
- Narrow claim scope, choosing when competing scopes exist, **15:23**

CLAIM CONSTRUCTION IN PATENT INFRINGEMENT —Cont'd

- Parent application, using prosecution history in subsequent applications, **15:22**
- Particular meaning disavowed in specification, **15:14**
- Pattern of examples in specification deduces claim meaning, **15:12**
- Permissive evidence, **15:6, 15:19**
- Post-grant review (PGR), using, **15:19.50**
- Preambles, **15:29**
- Prosecution history
 - disclaimer of ordinary meaning, **15:21**
 - intrinsic evidence, **15:19**
 - ordinary meaning is unclear, **15:20**
 - parent application, using prosecution history in subsequent applications, **15:22**
- Relative terminology, **15:25**
- Scope
 - differentiation of claims and interpreting claims of different scope, **15:24**
 - illustration regarding scope of "about," **15:26**
 - limiting claim scope, consistent with invention's purpose, **15:16**
 - narrow claim scope, choosing when competing scopes exist, **15:23**
- Specification clearly defines claim term, **15:10**
- Timing in view of issued patent, **15:27**
- Tools for generic company, **15:9**
- Trademark doctrinal law on surveys, using to assist in claim construction, **15:30**

**CLAIM CONSTRUCTION IN
PATENT INFRINGEMENT**

—Cont'd

Treatises as sources of claim
meaning, **15:7**

Underclaiming, **15:18**

**CLAIMING PRIORITY
PROVISIONALS,
CONTINUATIONS AND
DIVISIONALS**

Generally, **14:1 to 14:18**

Adequate disclosure to support
later filed applications,
importance of, **14:16**

Chains of priority, rolling
provisionals allow for, **14:16**

Concept of claiming priority or
benefit to earlier filing date,
14:1

Continuation applications
continuation-in-part applica-
tions, introducing new
matter, **14:15**

different invention using same
specification, **14:11**

Divisional applications
examiner-mandated restrictions
to different inventions,
14:13

safe harbor provision, **14:14**

Earlier filed foreign application,
claim for foreign priority to
include specific reference to,
14:6

Earliest filing dates, priority and,
14:3

Examiner-mandated restrictions to
different inventions,
divisional applications, **14:13**

Foreign priority dates to U.S. pro-
visional applications, claim-
ing, **14:4**

Importance of adequate disclosure
to support later filed applica-
tions, **14:17**

**CLAIMING PRIORITY
PROVISIONALS,
CONTINUATIONS AND
DIVISIONALS—Cont'd**

Mechanics of claiming priority
and benefits to earlier filing
dates, **14:7**

New matter, introducing, continu-
ation-in-part applications,
14:15

Prior art

before and after AIA, prior art
and § 119(a), **14:9**

provisional application prior art
date under pre-AIA
§ 102(e) and 102(a)(2),
14:5

tool for evaluating prior art
effect, **14:8**

Provisional patent applications
generally, **14:2**

foreign priority dates to U.S.
provisional applications,
claiming, **14:4**

prior art date under pre-AIA
§ 102(e) and 102(a)(2),
14:5

Rolling provisionals allow for
chains of priority, **14:16**

Safe harbor provision for
divisional applications, **14:14**

Section 119

earlier filed foreign application,
claim for foreign priority
to include specific refer-
ence to, **14:6**

foreign priority dates to U.S.
provisional applications,
claiming, **14:4**

prior art and § 119(a) before
and after AIA, **14:9**

provisional application prior art
date under pre-AIA
§ 102(e) and 102(a)(2),
14:5

tool for evaluating prior art
effect, **14:8**

INDEX

CLAIMING PRIORITY

PROVISIONALS, CONTINUATIONS AND DIVISIONALS—Cont'd

Sections 120 and 121

claiming benefit of earlier filed
applications, **14:10**

specific reference to earlier filed
application, **14:12**

Tool for evaluating prior art effect,
14:8

CLAIMS

Generally. **Patent Basics** (this
index)

CLINICAL TRIALS

**Brand Drug Approval and
Orange Book** (this index)

COMPETITIVE GENERIC

THERAPY (CGT)

INITIATIVE, 180-DAY

MARKET EXCLUSIVITY

Generally, **30:1 to 30:7**

Commentary, **30:5**

FDA waiting 75 days before
approving other ANDAs,
30:6

Inadequate generic competition,
30:3

Qualifying for CGT, **30:2**

Relevant statutory provisions of
180-day exclusivity and for-
feiture, **30:7**

Securing exclusivity and losing it,
30:4

COMPOUNDING

Generally, **36:1 to 36:5**

Animal drugs, **36:5**

False advertising, **36:4**

FDA authority, **36:2**

Patent infringement issues, **36:3**

CONFIDENTIAL ACCESS

OFFERS

Declaratory Judgment (this
index)

CONFIDENTIAL ACCESS

OFFERS—Cont'd

**Orange Book Patent Certifica-
tions** (this index)

CONSTRUCTION OF CLAIMS

**Claim Construction in Patent
Infringement** (this index)

CONTINUATION

APPLICATIONS

**Claiming Priority Provisionals,
Continuations and Division-
als** (this index)

CONTRIBUTORY AND

INDUCEMENT

INFRINGEMENT

Generally, **18:1 to 18:12**

Contributory patent infringement
under 35 U.S.C.A. § 271(c)

generally, **18:9**

knowing component is espe-
cially made, **18:10**

materiality, **18:12**

substantial, noninfringing uses,
18:11

Inducement patent infringement
under 35 U.S.C.A. § 271(b)

generally, **18:2**

mitigating or thwarting induce-
ment to infringe claims

generally, **18:5**

opinions of counsel of inva-
lidity to thwart specific
intent to induce infringe-
ment, **18:6**

pointing to other section of
label to prove inducement,
18:8

RLD label taken as a whole,
non-infringing uses, **18:3**

specific intent, pleading and
proving, **18:4, 18:6**

summary, **18:7**

unapproved FDA use, **18:8**

CONTRIBUTORY AND

INDUCEMENT

INFRINGEMENT—Cont'd

Knowing component is especially made, **18:10**

Materiality, **18:12**

RLD label taken as a whole, non-infringing uses, **18:3**

Specific intent, pleading and proving, **18:4, 18:6**

Substantial, noninfringing uses, **18:11**

COSTS

Inequitable conduct, award of fees and costs, **19:6**

COVENANTS

Declaratory Judgment (this index)

DAMAGES

Generally, **32:1 to 32:38**

America Invents Act of 2011, **32:28**

Attorneys' Fees (this index)

Enhanced damages and willful infringement

generally, **32:25**

factors to consider, **32:26**

filing ANDA, **32:30**

legal opinions, **32:27**

patent in reexamination, **32:29**

specifying facts in pleading, **32:31**

Exceptional circumstances.

Attorneys' Fees (this index)

Inequitable conduct, fraud-based damages, **19:7**

Lost profits

generally, **32:12, 32:18**

calculating, **32:22**

expenses

bringing into calculus, **32:22**

expense deductions, **32:23**

market reconstruction, **32:19**

DAMAGES—Cont'd

Lost profits—Cont'd

substitutes, existence of, **32:20**

substitutes and authorized generics, existence of, **32:21**

Money damages

generally, **32:10, 32:12**

enhanced damages and willful infringement, above

lost profits, above

pediatric exclusivity, **32:24**

permanent injunction, effect on, **32:17**

reasonable royalty, below

Pediatric exclusivity, money damages not permitted, **32:24**

Permanent injunction, effect on, **32:17**

Post-publication of patent to

patent issuance under provisional rights, patent damages for, **32:11**

Potential remedies for infringement, **32:2**

Reasonable royalty

generally, **32:12, 32:13**

factors to consider, **32:15, 32:16**

generic drug infringement, factors in relation to, **32:16**

Georgia Pacific test, **32:15**

hypothetical negotiations, **32:14**

Willful infringement. Enhanced damages and willful infringement, above

DECLARATORY JUDGMENT

Generally, **33:1 to 33:14**

Confidential access, offers for

generally, **33:13**

enforcement of offer as improper private right of action, **33:14**

Counterclaims based on section viii patents, **33:15**

INDEX

DECLARATORY JUDGMENT

—Cont'd

- Covenants
 - divesting court's jurisdiction, **33:11**
 - fear of suit, removing, **33:10**
 - not to sue, **33:10**
- Exclusivity, declaratory judgment triggering generally, **33:6**
- Orange Book listing and declaratory judgment jurisdiction
 - generally, **33:8**
 - patents listed but statutorily disclaimed, **33:9**
 - tentative approval, need for before filing action, **33:7**
- Famciclovir factors allowing declaratory judgment action, **33:5**
- Orange Book listing and declaratory judgment jurisdiction
 - generally, **33:8**
 - patents listed but statutorily disclaimed, **33:9**
- Post-MedImmune standards, **33:4, 33:5**
- Purpose of Declaratory Judgment Act, **33:1**
- Standards
 - post-MedImmune standards, **33:4, 33:5**
 - traditional standards, **33:3**
- Updates, **33:12 to 33:14**
- When used in pharmaceutical patent cases, **33:2**

DEFENSES

- Equitable Defenses** (this index)

DEFICIENCY LETTERS

- Abbreviated New Drug Application (ANDA)** (this index)

DEPENDENT CLAIMS (§ 112)

- Infringement and invalidity, **12:2**

DEPENDENT CLAIMS (§ 112)

—Cont'd

- Section 112(c)-(d) (pre-AIA § 112, third and fourth paragraph), **12:1**

DEVELOPMENT OF DRUGS

- Brand drug pathways, **1:1**
- Generic drug pathways, **1:2**
- Judges and lawyers, legal aspects of generic drug development, **1:3**

DIVISIONAL APPLICATIONS

- Claiming Priority Provisionals, Continuations and Divisionals** (this index)

DOCTRINE OF EQUIVALENTS (DOE) INFRINGEMENT

- Generally, **17:1 to 17:25**
- Applied to word “about,” **17:25**
- Conclusion, **17:24**
- Dedication to public rule, **17:8**
- Element-by-element analysis, **17:6**
- Ensnarement test for prior art, **17:7**
- Estoppel. Prosecution history estoppel (PHE) doctrine, below
- Federal Circuit summary of equivalency factors, **17:12**
- Festo test, **17:12 to 17:17**
- Foreseeable changes, **17:14, 17:15**
- Function way result test, **17:5, 17:22**
- Hypothetical claim analysis, **17:21**
- Insubstantial differences test, **17:4, 17:22**
- Other unexplained reason, **17:17**
- Prior art
 - ensnarement test, **17:7**
 - preclusions, **17:21**
- Prosecution history estoppel (PHE) doctrine
 - generally, **17:9**

**DOCTRINE OF EQUIVALENTS
(DOE) INFRINGEMENT**

—Cont'd

Prosecution history estoppel
(PHE) doctrine—Cont'd
alternate to insubstantial differences and function way result tests, **17:22**
amendment-based estoppel
generally, **17:10**
Festo test, **17:12 to 17:17**
foreseeable changes, **17:14, 17:15**
other unexplained reason, **17:17**
rebutting presumption of estoppel, **17:11**
rebutting prosecution history estoppel, **17:13**
tangential relationship, **17:16**
argument-based estoppel, **17:18**
detailed structure test, **17:22**
Federal Circuit summary of equivalency factors, **17:12**
Festo test, **17:12 to 17:17**
foreseeable changes, **17:14, 17:15**
hypothetical claim analysis, **17:21**
other unexplained reason, **17:17**
prior art preclusions, **17:21**
rebutting presumption of estoppel, **17:11**
rebutting prosecution history estoppel, **17:13**
related applications may evoke estoppel, **17:19**
scope, **17:20**
tangential relationship, **17:16**
Rebutting presumption of estoppel, **17:11**
Rebutting prosecution history estoppel, **17:13**
SmithKline Beecham and equivalency, sustained

**DOCTRINE OF EQUIVALENTS
(DOE) INFRINGEMENT**

—Cont'd

release bupropion, **17:23**
Subject matter disclosed but not claimed, **17:8**
Tangential relationship, **17:16**
Tests for DOE
generally, **17:2**
doctrine of equivalents limitations, **17:3**
element-by-element analysis, **17:6**
ensnarement test for prior art, **17:7**
function way result test, **17:5**
insubstantial differences test, **17:4**

ENABLEMENT (§ 112)

Generally, **9:1 to 9:13**
Common knowledge and inadvertent obviousness, gap filling enablement, **9:7**
Contrasting enablement and best mode, **9:13**
Effective amounts, patent invalidity theory, **9:12**
Experimentation, undue, **9:8**
How to make, patent invalidity theory, **9:9**
How to use, patent invalidity theory, **9:10**
In vitro and in vivo teaching, **9:11**
Lack of enablement, **9:6 et seq.**
Patent invalidity theories
generally, **9:5 to 9:12**
common knowledge and inadvertent obviousness, gap filling enablement, **9:7**
effective amounts, **9:12**
how to make, **9:9**
how to use, **9:10**
in vitro and in vivo teaching, **9:11**
lack of enablement, **9:6 et seq.**

INDEX

ENABLEMENT (§ 112)—Cont'd

- Patent invalidity theories—Cont'd
 - undue experimentation, **9:8**
- Role of specification, **9:1**
- Section 112(a) (pre-AIA § 112, first paragraph)
 - generally, **9:2**
 - basics of enablement requirement, **9:3**
 - quick summary, **9:4**
- Undue experimentation, **9:8**

ENANTIOMERS

- Generally, **3:3**
- Case studies, **3:3 to 3:8**
- Claim construction, **15:28**
- Clopidogrel, **3:8**
- History of patentability, **3:4**
- Levetiracetam, **3:7**
- Levofloxacin, **3:6**
- Obviousness and invalidity, **7:30**
- Racemate known, patentability, **3:5**
- Three-year exclusivity, **23:14**

EQUITABLE DEFENSES TO PATENT INFRINGEMENT

- Generally, **20:1 to 20:15**
- Claim preclusion, **20:2**
- Collateral estoppel, **20:2**
- Equitable Estoppel** (this index)
- Implied license
 - generally, **20:13**
 - litigation settlement, **20:15**
 - sales of products, **20:14**
- Issue preclusion, **20:2**
- Laches** (this index)
- Other defenses under 35 U.S.C.A. § 282, **20:12**
- Res judicata, **20:2**

EQUITABLE ESTOPPEL

- Generally, **20:8**
- Factors, **20:8**
- Laches compared, **20:5**
- Presumptions, **20:9**

EQUIVALENTS

- Doctrine of Equivalents**
 - Infringement** (this index)

ESTOPPEL

- Doctrine of Equivalents**
 - Infringement** (this index)
- Equitable Estoppel** (this index)

EVIDENCE

- Claim Construction in Patent Infringement** (this index)

EXCLUSIVITIES

- Brand Side Exclusivities** (this index)
- Competitive Generic Therapy (CGT) Initiative, 180-Day Market Exclusivity** (this index)
- Data exclusivity and market exclusivity, difference between, **26:3.50**
- Declaratory Judgment** (this index)
- Paragraph IV Based 180-Day Exclusivity** (this index)

EXTENDED RELEASE

FORMULATIONS

- Abbreviated New Drug Application (ANDA)** (this index)
- Obviousness and invalidity, **7:30**

FALSE ADVERTISING

- Compounding, **36:4**

FORFEITURE

- Abbreviated New Drug Application (ANDA)** (this index)
- Paragraph IV Based 180-Day Exclusivity** (this index)

FRAUD

- Inequitable Conduct** (this index)
- Patent Office, fraud on, **19:1**

GENERIC COMPANIES

- Citizen petitions, **34:7**

GENERIC PRODUCTS

Size, shape, or color
generally, **35:1 to 35:3**
cases, **35:3**
functionality, infringement
defense, **35:2**

GENUS AND SPECIES

Generally, **13:1 to 13:5**
Anticipation of patents, **13:2**
Case study, Zyprexa (Olanzapine),
13:5
Obviousness, **13:3**
What is, **13:1**
Written description support for
genus in view of disclosure
of species, **13:4**

IMPLIED LICENSE

Equitable Defenses (this index)

INDEFINITENESS (§ 112)

Generally, **11:1 to 11:5**
Ability to measure and testing,
failure of, **11:3**
Claim amendments to avoid ambi-
guity, indefiniteness and
rebuttable presumption, **11:5**
Claim precision and boundaries,
11:1, 11:2
Rebuttable presumption and
indefiniteness in claim
amendments to avoid ambi-
guity, **11:5**
Section 112(b) (pre-AIA § 112,
second paragraph), **11:1, 11:2**
What inventor regards as inven-
tion, **11:4**

INDIRECT INFRINGEMENT

**Contributor and Inducement
Infringement** (this index)

INDUCEMENT

INFRINGEMENT

**Contributor and Inducement
Infringement** (this index)

INEQUITABLE CONDUCT

Generally, **19:1 to 19:44**
Affidavits
affiant's relationship to
applicant, failure to dis-
close, **19:18**
false or misleading, **19:36**
Asserting inequitable conduct,
19:10, 19:11
Attorneys' fees and costs, award-
ing, **19:6**
Best mode violations when inva-
lidity not allowed, using
inequitable conduct to chal-
lenge, **8:6**
Burying critical reference, **19:34**
Common situations, **19:3**
Conclusion, **19:44**
Corrective measures, **19:38**
Cultivated ignorance, **19:33**
Curing inequitable conduct, **19:9**
Damages, fraud-based, **19:7**
Deception. Intent to deceive,
below
Duty of candor and good faith
during
post issue PTAB trials, **19:42**
PTE applications, **19:41**
Duty of candor during mainte-
nance fee payments, **19:43**
False or misleading affidavits,
19:36
False statements, **19:17**
Foreign language documents,
obtaining translations, **19:33**
Foreign office actions, failure to
disclose, **19:35**
Fraud
damages, fraud-based, **19:7**
Patent Office, fraud on, **19:1**
private enforcement, **19:8**
Walker Process fraud, **19:7**
Gross negligence, **19:28, 19:29**
Heightened pleading standards,
19:11

INDEX

INEQUITABLE CONDUCT

—Cont'd

- Infectious unenforceability, **19:5**
- Inference of intent, mere denial never enough to overcome, **19:30**
- Intent to deceive
 - generally, **19:26 to 19:37**
 - affidavits, false or misleading, **19:36**
 - burying critical reference, **19:34**
 - cultivated ignorance, **19:33**
 - false or misleading affidavits, **19:36**
 - foreign language documents, obtaining translations, **19:33**
 - foreign office actions, failure to disclose, **19:35**
 - gross negligence, **19:28, 19:29**
 - inference of intent, mere denial never enough to overcome, **19:30**
 - patterns of misrepresentations or omissions, **19:32**
 - prior art, below
 - proper inventors, failure to name, **19:37**
 - single actions, **19:32**
 - submitted prior art, stressing importance, **19:27**
 - totality, including gross negligence, **19:29**
- Litigation misconduct as patent unenforceability, **19:40**
- Materiality threshold
 - generally, **19:12 et seq.**
 - affiant's relationship to applicant, failure to disclose, **19:18**
 - corrective measures, **19:38**
 - current and past tests, **19:12**
 - false statements, **19:17**
 - information does not have to be claimed, **19:13**

INEQUITABLE CONDUCT

—Cont'd

- Materiality threshold—Cont'd
 - information does not have to be verbatim, **19:16**
 - information not updated, **19:20**
 - petitions to make special, **19:20**
 - pitfalls for applicants, **19:38**
 - practice tips, **19:38**
 - presumption that data is material, **19:19**
 - section 112(1), failure to comply, **19:15**
 - unfavorable test results, failure to provide, below
- Mere denial never enough to overcome inference of intent, **19:30**
- Patterns of misrepresentations or omissions, **19:32**
- Penalties
 - generally, **19:4**
 - attorneys' fees and costs, awarding, **19:6**
 - fraud, above
 - unenforceability, **19:5**
- Pitfalls for applicants, **19:38**
- Pleading inequitable conduct
 - under heightened pleading standards, **19:11**
- Post-Therasense cases, recap, **19:39**
- Practice tips, **19:38**
- Presumption that data is material, **19:19**
- Prior art
 - failure to disclose, **19:35**
 - searching for, **19:31**
 - submitted prior art, stressing importance, **19:27**
- Private enforcement of fraud, **19:8**
- Proper inventors, failure to name, **19:37**
- Section 112(1), failure to comply, **19:15**

INEQUITABLE CONDUCT

—Cont'd

- Single actions, **19:32**
- Test results. Unfavorable test results, failure to provide, below
- Types of inequitable conduct test, **19:3**
- Unenforceability
 - infectious unenforceability, **19:5**
 - litigation misconduct, **19:40**
- Unfavorable test results, failure to provide
 - generally, **19:21**
 - affirmative misrepresentations, **19:25**
 - claim for priority, **19:23**
 - issues examiner focuses on, **19:24**
 - test conditions, accurate description, **19:22**
- Walker Process fraud, **19:7**

INFRINGEMENT

- Brand side exclusivities, patent infringement implications, **23:26**
- Claim Construction in Patent Infringement** (this index)
- Contributor and Inducement Infringement** (this index)
- Damages** (this index)
- De minimis infringement, **21:12**
- Doctrine of Equivalents Infringement** (this index)
- Equitable Defenses** (this index)
- Future infringement, enjoining, **32:6, 32:8**
- Injunctive Relief** (this index)
- Literal Infringement** (this index)
- Remedies** (this index)
- Safe Harbor Exemptions** (this index)

INHALERS

Abbreviated New Drug Application (ANDA) (this index)

INJUNCTIVE RELIEF

- At-risk launch, preventing, **32:6, 32:7**
- Damages, effect on permanent injunction, **32:17**
- Future infringement, stopping generally, **32:6**
 - when generic company loses, **32:8**
- Inter partes review instituted to deny TRO or preliminary injunction, **31:9**
- Thirty-Month Stay, this index

INTENT

- Enhanced damages and willful infringement. **Damages** (this index)
- Intentional forfeiture of 180-day exclusivity, **29:35**
- Intent to deceive. **Inequitable Conduct** (this index)
- Specific intent, pleading and proving, contributory and inducement infringement, **18:4, 18:6**

INTER PARTES REVIEW (IPR)

- Claim construction in patent infringement, **15:19.50**
- Cleaning up patent quality before or after patent issues, **31:1**
- Interjecting into pending application, preissuance submissions, **31:2**
- Invalidating patent, post-issuance procedures, **31:3**
- Parallel patent litigation, potential impacts of IPRs
 - generally, **31:5 to 31:12**
 - causing forfeiture of 180-day exclusivity by getting court

INDEX

INTER PARTES REVIEW (IPR)

—Cont'd

- Parallel patent litigation, potential impacts of IPRs—Cont'd
 - decision for failure to market, **31:12**
 - denial of IPR petition and subjective effect of perceptual estoppel, **31:7**
 - instituted IPR to deny TRO or preliminary injunction, **31:9**
 - patentee losing at PTAB, **31:11**
 - petitioner losing at PTAB, **31:10**
 - timing of IPR, appeals and standing to appeal, **31:6**
 - using denied IPR petition as roadmap to correct or summary judgment if no invalidity, **31:8**
- Pending review, impact on 30-month stays, **27:27**
- Post-grant review (PGR) and inter partes review, **31:4**
- Pre-issue submissions and post-issuance IPR with impacts on court litigation
 - generally, **31:1 to 31:12**
 - cleaning up patent quality before or after patent issues, **31:1**
 - interjecting into pending application, preissuance submissions, **31:2**
 - invalidating patent, post-issuance procedures, **31:3**
 - parallel patent litigation, potential impacts of IPRs, above
 - post-grant review (PGR) and inter partes review, **31:4**

INVALIDITY

- Clinical trials, public use patent invalidity, **22:21**

INVALIDITY—Cont'd

- Enablement, patent invalidity theories. **Enablement** (this index)
- Validity and Invalidity, Foundations of** (this index)

INVESTIGATIONAL NEW DRUG APPLICATION (IND)

Brand Drug Approval and Orange Book

JURISDICTION

- Declaratory Judgment** (this index)

LACHES

- Generally, **20:3**
- Equitable estoppel compared, **20:5**
- Factors, **20:6**
- Post-SCA Hygiene, **20:4**
- Presumptions, **20:7**
- Prosecution laches, **20:10, 20:11**

LICENSES

- Implied license. **Equitable Defenses** (this index)

LISTABLE AND NONLISTABLE PATENTS

Brand Drug Approval and Orange Book

LITERAL INFRINGEMENT

- Generally, **16:1 to 16:8**
- ANDA
 - current ANDA infringement for future modifications, **16:8**
 - infringement inquiry, ANDA specification controls, **16:7**
- Federal Circuit review of record, **16:2**
- Generic drug application, literal infringement as based on, **16:6**
- Impact of *SmithKline v. Apotex* on infringement, **16:4**

LITERAL INFRINGEMENT

—**Cont'd**

- Litigating more than one claim construction at trial, **16:2**
- Proving, **16:5**
- Single crystal theory, inherent infringement under generally, **16:3**
- impact of SmithKline v. Apotex on infringement, **16:4**

LITIGATION

- Frivolous litigation by brand company, award of attorneys' fees, **32:38**
- Implied license by litigation settlement, **20:15**
- Parallel patent litigation, potential impacts of IPRs. **Inter Partes Review** (this index)
- Pre-issue submissions and post-issuance IPR with impacts on court litigation. **Inter Partes Review** (this index)
- Unenforceability, litigation misconduct, **19:40**

LOSS OF RIGHTS

- Novelty and Loss of Rights** (this index)

LOST PROFITS

- Damages** (this index)

MATERIALITY

- Inequitable Conduct** (this index)

MEANS PLUS FUNCTION

CLAIMS (§ 112)

- Section 112(f) (pre-AIA § 112, sixth paragraph), **12:3**

MEDICAID

- Best price law, **28:13**

MISCONDUCT

- Litigation misconduct as patent unenforceability, **19:40**

NEW CHEMICAL ENTITY (NCE)

- Brand Side Exclusivities** (this index)

NEW DRUG APPLICATIONS

Abbreviated New Drug Application (ANDA) (this index)

Brand Drug Approval and Orange Book (this index)

NOTICE LETTER

- Orange Book Patent Certifications** (this index)

NOVELTY AND LOSS OF RIGHTS (§ 102)

- Generally, **6:1 to 6:25**
- AIA, novelty under, **6:2**
- Anticipation, express, **6:18**
- Anticipation, inherent generally, **6:20 to 6:25**
- accidental anticipation, **6:22**
- element-by-element analysis, **6:18**
- hypothetical, **6:24**
- necessarily present/natural result, **6:21**
- recognition of the inherent element, **6:23**
- SmithKline v. Apotex revisited, **6:25**
- Anticipation by equivalency, **6:19**
- Conclusion, **6:16**
- Element-by-element analysis, **6:18**
- Equivalency, anticipation by, **6:19**
- Express anticipation, **6:18**
- Inherent anticipation. Anticipation, inherent, above
- Invalidating patent, invention not new, **6:17**
- Joint inventorship, **6:15**
- New inventions, **6:1**
- Old § 102(a), **6:3**
- Old § 102(b) generally, **6:4**

INDEX

NOVELTY AND LOSS OF

RIGHTS (§ 102)—Cont'd

- Old § 102(b)—Cont'd
 - on-sale bar, **6:5**
 - public use bar, **6:6**
- Old § 102(c), **6:8**
- Old § 102(d), **6:9**
- Old § 102(e)
 - example and time lines,
 - understanding § 102(e) through, **6:11**
 - utopian-world patent issuance in USPTO, **6:10**
- Old § 102(f), inventor is not inventor, **6:12**
- Old § 102(g)
 - contrasting § 102(g)(1) vs. 102(g)(2), **6:14**
 - prior invention by another, **6:13**
- Public use by selling/testing samples via technology transfer and licensing, **6:7**
- SmithKline v. Apotex revisited, **6:25**

OBVIOUSNESS (§ 103)

- Generally, **7:1 to 7:39**
- Active ingredient, **7:12**
- Analogue of compound, attacking, **7:38**
- Benign factor in obviousness, **7:11**
- Breaking compound patents, **7:35**
- Chemical similarity
 - generally, **7:18**
 - homology, isomerism and structural similarity, **7:18**
 - isomers and obviousness, **7:20**
 - structural obviousness of chemical compounds, **7:19**
- Combination of references, **7:5**
- Combining prior art elements
 - according to known methods to yield predictable results, **7:24**
- Commercial success, generic drug infringement cases, **7:15**

OBVIOUSNESS (§ 103)—Cont'd

- Common sense, role of, **7:29**
- Conclusion, **7:21**
- Copying by others
 - generally, **7:11**
 - active ingredient, **7:12**
 - benign factor in obviousness, **7:11**
 - formulation, **7:13**
- Design considerations, **7:31**
- Failure of others to make invention, **7:10**
- Finite number of items, choosing from, **7:28**
- Formulation, **7:13**
- Genus and species, **13:3**
- Graham v. Deere factors, **7:2**
- Hindsight, guarding against, **7:4**
- Homology, isomerism and structural similarity, **7:18**
- Invalidity, obviousness and, **7:22 to 7:39**
- Isomers and obviousness, **7:20**
- Known techniques
 - applying to yield predictable results, **7:27**
 - improving similar devices, methods or products, **7:26**
- Lansoprazole vs. rabeprazole, structural obviousness, **7:37**
- Lead compound analysis
 - generally, **7:35, 7:36**
 - copying lead compound test, **7:39**
 - new lead formulation test, **7:39**
 - pioglitazone case study, **7:36**
- Licensing by others, **7:14**
- Long felt need for invention, **7:9**
- Market forces, **7:31**
- Motivation, suggestion, teaching (MST) in prior art, **7:4, 7:32**
- Obvious to try
 - generally, **7:28**
 - common sense, role of, **7:29**

OBVIOUSNESS (§ 103)—Cont'd

Obvious to try—Cont'd
 enantiomers, salt selection and extended release formulations, applicability to, **7:30**
 finite number of items, choosing from, **7:28**
 Person of ordinary skill in the art (POSITA), **7:33, 7:34**
 Pioglitazone case study, structural obviousness, **7:36**
 Praise and awards from third parties, **7:17**
 Predictable results
 combining prior art elements according to known methods to yield predictable results, **7:24**
 known techniques, applying to yield predictable results, **7:27**
 simple substitution of one known element for another to obtain predictable results, **7:25**
 Primary factors, **7:2**
 Prior art
 combining prior art elements according to known methods to yield predictable results, **7:24**
 flowing from prior art, **7:5**
 motivation, suggestion, teaching (MST), **7:4, 7:32**
 References
 combination of references, **7:5**
 from nature of problem to be solved, **7:6**
 Secondary indicia, **7:7**
 Simple substitution of one known element for another to obtain predictable results, **7:25**
 Skepticism by others and proof of nonobviousness, **7:16**
 Structural obviousness
 generally, **7:35 to 7:38**

OBVIOUSNESS (§ 103)—Cont'd

Structural obviousness—Cont'd
 analogue of compound, attacking, **7:38**
 breaking compound patents, **7:35**
 chemical compounds, **7:19**
 lansoprazole vs. rabeprazole, **7:37**
 lead compound analysis, **7:35, 7:36**
 pioglitazone case study, **7:36**
 Third-party praise and awards, **7:17**
 Timing of inquiry, **7:3**
 Trivial variations, inventions more than, **7:1**
 Unexpected results of invention, **7:8**
 USPTO guidelines, **7:23**

ORANGE BOOK

Over the counter (OTC) drugs, **37:2**

ORANGE BOOK PATENT CERTIFICATIONS

ANDA certifications
 amendments to pending ANDA trigger obligations to update certifications, **26:40**
 current RLD itself referred to previous RLD, **26:6**
 data exclusivity and market exclusivity, difference between, **26:3.50**
 impact on ANDA approval, **26:7**
 no Orange Book patent existing during NCE five year exclusivity, **26:4**
 paragraph IV certification, adding in pending ANDA, **26:41**
 updating paragraph IV certification when changes occur to ANDA formulation, **26:37**

INDEX

ORANGE BOOK PATENT

CERTIFICATIONS—Cont'd

ANDA certifications—Cont'd
when to file, **26:3, 26:4**

Brand Drug Approval and Orange Book (this index)

Carve outs. Section viii state-
ments, below

Combining paragraph I certifica-
tion in lieu of section viii
statement, **26:16**

Data exclusivity and market
exclusivity, difference
between, **26:3.50**

Declaratory judgment jurisdiction,
Orange Book listing, **33:8,**
33:9

Delisting patents from Orange
Book

before NCE-1 date to thwart
generic filings, **23:9**

date-certain forfeiture event,
delisting to create, case
studies, **29:9 to 29:11**

Exclusivity

data exclusivity and market
exclusivity, difference
between, **26:3.50**

Paragraph IV Based 180-Day Exclusivity (this index)

FDA

tracking paragraph IV certifica-
tions on FDA web site,
26:36

updating on notice letters, **26:30**

Hypothetical patent certifications,
26:8

Mechanics of Orange Book patent
certifications and notice let-
ters, **26:1 et seq.**

New or rollover patents requiring
new certifications, **26:31,**
26:32

Notice letter. Paragraph IV certifi-
cation and notice letter
requirements, below

ORANGE BOOK PATENT

CERTIFICATIONS—Cont'd

Offer for confidential access
(OCA)

generally, **26:33**

issues with Officer for

Confidential Access, **26:35**

where invalidity alleged, **26:34**

Paragraph IV certification and
notice letter requirements

generally, **26:17**

antitrust injury, predicate to,
26:25

appending letter to complaint,
26:24

claims not normally listable,
details on, **26:22**

content and sufficiency of
notice letter, **26:20**

detail requirements, **26:21 to**
26:23

exclusivity (180-day),
paragraph IV based.
**Paragraph IV Based 180-
Day Exclusivity** (this
index)

filing split section viii carve
outs and paragraph IV
certifications in single
patent, **26:38**

form of letter of detailed state-
ment, **26:23**

how to send notice letter, **26:26**

identifying patents in notice
letter, **26:19**

just one claim of just one
patent, **26:18**

pending ANDA, adding
paragraph IV certification,
26:41

sending letter before ANDA is
officially submitted/
received, **26:29**

sending letter not a waiver of
privilege, **26:39**

ORANGE BOOK PATENT

CERTIFICATIONS—Cont'd

- Paragraph IV certification and notice letter requirements—Cont'd
 - tracking paragraph IV certifications on FDA web site, **26:31**
 - updating FDA on notice letters, **26:30**
 - updating when changes occur to ANDA formulation, **26:37**
 - when to send notice letter, **26:28**
 - where to send notice letter, **26:27**
- Patent certifications and Orange Book listing
 - generally, **26:2, 26:5**
 - late listed patents, **26:5.50**
 - paragraph I, II, III or IV certifications, **26:5**
 - pop up certifications, **26:5.50**
- Patent information and Orange Book. **Brand Drug Approval and Orange Book** (this index)
- Reissue patents, **26:31, 26:32**
- Section viii statements
 - carve outs
 - generally, **26:11**
 - filing split section viii carve outs and paragraph IV certifications in single patent, **26:38**
 - indications to unlisted patents, **26:13**
 - suitability petitions, using to allow carve out, **26:15**
 - combining paragraph I certification in lieu of section viii statement, **26:16**
 - currently unlisted method of use patent, requesting listing of, **26:14**

ORANGE BOOK PATENT

CERTIFICATIONS—Cont'd

- Section viii statements—Cont'd
 - indications to unlisted patents, carving out, **26:13**
 - omitting patented methods of use, **26:9, 26:10**
 - one and only indication, **26:12**
 - Sertraline, **26:11**
 - suitability petitions, using to allow carve out, **26:15**
 - use codes, patent infringement and carve-outs, **26:10**
 - working example, **26:11**
- Thirty-month stay, frozen Orange Book, **27:3**
- Tracking paragraph IV certifications on FDA web site, **26:36**
- Updating FDA on notice letters, **26:30**
- Viagra case study, **26:8**

ORPHAN DRUGS

- Exclusivity, **23:15**

OVER THE COUNTER (OTC) DRUGS

- Generally, **37:1 to 37:5**
- ANDA filing against OTC NDA drug product, **37:3**
- Considerations for 180-day exclusivity in Rx to OTC switch, **37:6**
- Orange book, **37:2**
- Prescription to OTC switches, **37:4**
- ANDA commercial issues, **37:5**

PAPER NDA

- Brand Drug Approval and Orange Book** (this index)

PARAGRAPH IV BASED 180-DAY EXCLUSIVITY

- Generally, **28:1 to 28:19**
- Adding new para. IV certification, immediate forfeiture, **29:19**

INDEX

PARAGRAPH IV BASED

180-DAY EXCLUSIVITY

—Cont'd

- Against whom 180-day exclusivity applies, **28:3**
- Court decision to trigger exclusivity now part of forfeiture scheme, **28:9.50**
- Creating 180-day exclusivity, **28:2**
- Delisting Orange Book patents to create date-certain forfeiture event, case studies, **29:9 to 29:11**
- Failure to market
 - generally, **29:3**
 - forfeiture provisions, **29:3**
 - little (aa), **29:4, 29:8**
 - little (bb)
 - generally, **29:5**
 - court decision triggering, **29:5.50 to 29:5.70, 31:12**
 - New America Invents Act procedures, **29:7**
 - rationale for little (bb)'s patent position vs. little (aa)'s regulatory position, **29:8**
 - no delisting and no litigation, **29:12**
 - thirty months to approval, 75 days to market, **29:4**
- Forfeiture of 180-day exclusivity
 - generally, **29:1 to 29:35**
 - adding new para. IV certification, immediate forfeiture, **29:19**
 - amendment of certification, **29:16**
 - ANDA review backlog possibly causing forfeitures, **29:28**
 - coercive agreements, **29:13, 29:14**
 - consequences for forfeiting applicant, **29:32**

PARAGRAPH IV BASED

180-DAY EXCLUSIVITY

—Cont'd

- Forfeiture of 180-day exclusivity
 - Cont'd
 - delisting Orange Book patents to create date-certain forfeiture event, case studies, **29:9 to 29:11**
 - estoppel effect of judgment, **29:6**
 - expiration of patents
 - generally, **29:30**
 - multiple patents confer exclusivity, **29:31**
 - failure to market, above
 - filing ANDA too early, **29:34**
 - forfeiture provisions, **29:2**
 - general policy terms, **29:33**
 - immediate forfeiture, adding new para. IV certification, **29:19**
 - intentional forfeiture, **29:35**
 - multiple patents confer exclusivity, **29:31**
 - New America Invents Act procedures and little (bb), **29:7**
 - no rolling exclusivity, **29:29**
 - settling lawsuits but maintaining paragraph IV to avoid forfeit, **29:13, 29:14**
 - tentative approval, failure to obtain in 30 months
 - generally, **29:17**
 - calculating 30 months, **29:20 et seq.**
 - case study, **29:25**
 - changed conditions, **29:26, 29:27**
 - citizen petitions, **29:26**
 - concurrent qualification and forfeiture, **29:19**
 - impact of GMP compliance, **29:18**

**PARAGRAPH IV BASED
180-DAY EXCLUSIVITY**

—Cont'd

Forfeiture of 180-day exclusivity
 —Cont'd
 tentative approval, failure to
 obtain in 30 months
 —Cont'd
 new FDASIA law, **29:21,**
 29:22
 no forfeiture due to changed
 conditions, **29:27**
 policy considerations, **29:24**
 vacation of judgment to avoid
 estoppel, **29:6**
 vested property rights, **29:33**
 withdrawal of application,
 29:15
 Generics, authorized
 generally, **28:12**
 curbing by Medicaid Best Price
 law, **28:13**
 Little (bb). Failure to market,
 above
 Mechanics of selective waiver and
 total relinquishment, **28:16**
 Medicaid best price law, **28:13**
 Natural expiration with underlying
 patent, **28:6**
 Patent-by-patent approach to
 patent certifications in pre-
 MMA December 2003, **28:4**
 Pediatric exclusivity and ability to
 obtain almost 12-months
 exclusivity, **28:19**
 Pop-up patents, effect on ANDA
 filers, **28:18**
 Product-by-product approach to
 exclusivity, **28:5**
 Reissue patents and new 180-day
 exclusivities, **28:11**
 Relinquishment. Waiver or
 relinquishment of exclusivity,
 below
 Settling lawsuits but maintaining
 paragraph IV to avoid forfeit,
 29:13, 29:14

**PARAGRAPH IV BASED
180-DAY EXCLUSIVITY**

—Cont'd

Strategy to file with split
 paragraph III/IV, converting
 to paragraph IV later and
 sharing co-exclusivity, **28:17**
 Tentative approval, failure to
 obtain in 30 months. Forfeiture
 of 180-day exclusivity,
 above
 Tracking 180-day exclusivity,
 28:10
 Triggering 180-day clock
 generally, **28:7**
 court decision to trigger
 exclusivity now part of
 forfeiture scheme, **28:9.50**
 post-MMA rules, **28:9**
 pre-December 2003 MMA
 rules, **28:8**
 Waiver or relinquishment of
 exclusivity
 generally, **28:14**
 joint exclusivity holders, **28:15**
 mechanics of selective waiver
 and total relinquishment,
 28:16
 multiple first applicants, **28:15**

PATENT BASICS

Generally, **2:1 to 2:11**
 Application process, **2:2**
 Body of claim, **2:9**
 Claims
 generally, **2:4 to 2:10**
 conclusion, **2:10**
 importance of patent claims, **2:4**
 organizational structure, below
 person of ordinary skill in the
 art (POSITA), **2:5**
 Common statutory provisions,
 2:11
 Importance of patent claims, **2:4**
 Organizational structure of claim
 generally, **2:6**

INDEX

PATENT BASICS—Cont'd

- Organizational structure of claim
 - Cont'd
 - body of claim, **2:9**
 - preamble, **2:7**
 - transition phase, **2:8**
- Person of ordinary skill in the art (POSITA), **2:5**
- Preamble, **2:7**
- Statutory provisions, **2:11**
- Structural organization of patent, **2:3**
- Transition phase, **2:8**
- Types of patents. **Pharmaceutical Patents, Common Types, this index**
- Validity and Invalidity, Foundations of** (this index)

PEDIATRIC EXCLUSIVITY

- Brand Side Exclusivities** (this index)

PERSON OF ORDINARY SKILL IN THE ART (POSITA)

- Generally, **2:5**
- Obviousness and invalidity
 - generally, **7:33**
 - ordinary skilled artisan not inventor, **7:34**

PETITIONS

- Citizen Petitions** (this index)
- Orange Book, using suitability petitions to allow carve outs, **26:15**
- Parallel patent litigation. **Inter Partes Review** (this index)

PHARMACEUTICAL PATENTS, COMMON TYPES

- Generally, **3:1 to 3:19**
- Base chemical/compound claims, **3:1**
- Claim types in polymorphs, **3:10**
- Combination of APIs, **3:13**
- Enantiomers** (this index)

PHARMACEUTICAL PATENTS, COMMON TYPES—Cont'd

- Esters, **3:2**
- Formulations, **3:14**
- Method of manufacture or process claims, **3:16**
- Methods of use, **3:15**
- Polymorphs
 - generally, **3:9**
 - amorphous to crystal form conversion and implications, **3:11**
- Product-by-process claims
 - generally, **3:17**
 - infringement and invalidity, steps for, **3:18**
- Release profiles, **3:19**
- Salts, **3:2**
- Solvates, **3:2**
- Typical litigation issues in polymorphism, **3:12**

POLYMORPHS

- Generally, **3:9**
- Amorphous to crystal form conversion and implications, **3:11**

PRESUMPTIONS

- DOE infringement, rebutting presumption of estoppel, **17:11**
- Equitable estoppel, **20:9**
- Laches, **20:7**
- Materiality of data, **19:19**

PRIOR ART

- Generally, **4:3 to 4:9**
- Burdens of proof, prior art considered or not considered by examiner
 - generally, **4:3 to 4:7**
 - cited but not vetted, **4:6**
 - fully presented and vetted, **4:5**
 - not cited, **4:7**
 - sources, **4:4**

PRIOR ART—Cont'd

Claiming Priority Provisionals, Continuations and Divisionals (this index)

Doctrine of Equivalents

Infringement (this index)

Inequitable Conduct (this index)

Obviousness (this index)

Practicing prior art

defense to infringement, **4:8**

replicating examples, inherent anticipation, **4:9**

PRIORITY

Claiming Priority Provisionals, Continuations and Divisionals (this index)

PROSECUTION HISTORY

Claim Construction in Patent Infringement (this index)

Estoppel. **Doctrine of Equivalents Infringement** (this index)

RECALL

Generic products in marketplace, **32:9**

REFERENCE LISTED DRUG

Abbreviated New Drug Application (ANDA) (this index)

REFUSAL TO RECEIVE (RTR)

Abbreviated New Drug Application (ANDA) (this index)

RELINQUISHMENT

Paragraph IV Based 180-Day Exclusivity (this index)

REMEDIES

ANDA and remedies for patent infringement

impact of loss on ANDA approval status, **32:3**

redating ANDA approval date generally, **32:3**

REMEDIES—Cont'd

ANDA and remedies for patent infringement—Cont'd
redating ANDA approval date—Cont'd

infringing activities under § 271(a), (b) and (c), **32:4**

old antibiotics, **32:5**

Damages (this index)

Declaratory Judgment (this index)

Injunctive Relief (this index)

Potential remedies, **32:2**

Recall of generic products in marketplace, **32:9**

ROYALTIES

Damages (this index)

SAFE HARBOR EXEMPTIONS

Generally, **21:1 to 21:14**

Ancillary activities, **21:10**

Chain of exemption

generally, **21:8 to 21:10**

ancillary activities, **21:10**

generic drug development, **21:9**

Common law research exemption, **21:12**

Congressional action on scope, effect of, **21:7**

De minimis infringement, **21:12**

Divisional applications, **14:14**

Generic drug development

chain of exemption, **21:9**

exemption not limited to, **21:13**

Genesis of exemption, **21:2**

Hatch Waxman Act, **21:3**

Information development and information submission to FDA, **21:4**

Inventory, stockpiling, **21:14**

Medical devices, **21:6**

Ostensibly unrelated activities, **21:6**

Recourse for patent holders, **21:11**

INDEX

SAFE HARBOR EXEMPTIONS

—Cont'd

- Research exemption, common law, **21:12**
- Roche v. Bolar, **21:2**
- Scope of exemption
 - generally, **21:3**
 - ancillary activities, **21:10**
 - chain of exemption, **21:8 to 21:10**
 - congressional action on scope, effect of, **21:7**
 - generic drug development, **21:9**
 - medical devices, **21:6**
 - ostensibly unrelated activities, **21:6**
 - reasonable scope, **21:5 to 21:10**
- Stockpiling inventory, **21:14**

SAMPLES

- ANDA, patent issues in samples, **25:51**

SECTION 112

- Best Mode** (this index)
- Dependent and means plus function claims, **12:1, 12:3**
- Dependent claim infringement and invalidity, **12:2**
- Enablement** (this index)
- Indefiniteness** (this index)
- Written Description** (this index)

SPECIES

- Genus and Species** (this index)

STAYS

- Thirty-Month Stay, this index

SUBJECT MATTER AND

UTILITY (§ 101)

- Generally, **5:1 to 5:18**
- Data comparisons with mental steps or analogous human mental work, pharmaceuticals and concepts related to, **5:7**

SUBJECT MATTER AND

UTILITY (§ 101)—Cont'd

- Diagnostic claims treatment, summary, **5:16**
- Diagnostics v. method claims, **5:15**
- Litigation strategies for § 101 invalidity, **5:13**
- Mayo two-part test, **5:2**
- Method of preparation claims, summary, **5:18**
- Method of treatment claims, summary, **5:17**
- Organizing or analyzing information, pharmaceuticals and concepts related to, **5:8**
- Patentable subject matter
 - generally, **5:1 et seq.**
 - Mayo two-part test, **5:2**
 - pharmaceutical patent subject matter, below
 - printed matter doctrine, **5:3, 5:4**
- Pharmaceutical patents
 - generally, **5:5 et seq.**
 - USPTO guidelines, **5:6**
- Pharmaceutical patent subject matter
 - data comparisons with mental steps or analogous human mental work, pharmaceuticals and concepts related to, **5:7**
 - organizing or analyzing information, pharmaceuticals and concepts related to, **5:8**
 - selected cases, **5:14**
- Pharmaceutical patent utility
 - generally, **5:9 to 5:12**
 - enablement, **5:11**
 - priority application dates, benefits of, **5:12**
 - specific methods of use of compound, **5:10**

**SUBJECT MATTER AND
UTILITY (§ 101)—Cont'd**

Printed matter doctrine
generally, **5:3**
two-part test, **5:4**
USPTO guidelines for pharma
patents, **5:6**

TENTATIVE APPROVAL

**Abbreviated New Drug Applica-
tion (ANDA)** (this index)
Failure to obtain in 30 months,
forfeiture of 180-day
exclusivity. **Paragraph IV
Based 180-Day Exclusivity**
(this index)

THIRTY-MONTH STAY

Generally, **27:1 to 27:27**
Cases extending or shortening
stay, **27:13, 27:15**
Counting days, **27:2**
Court decision
court made no decision, stay
extended, **27:10**
stay of decision pending appeal
to maintain 30-month stay
intact, **23:8, 27:25**
termination of stay, **27:6**
Creating stay, **27:2**
December 2003 rules, earning
stays under, **27:20**
Delays, effect of, **27:17**
Extending stay
cases extending stay, **27:13**
court made no decision, **27:10**
generic company filed too early,
request to elongate stay to
avoid forfeiture, **27:14**
lack of cooperation, **27:12**
Frozen Orange Book, **27:3**
Inter partes review, pending,
impact on stays, **27:27**
Lack of cooperation, lengthening
or shortening due to, **27:12**
Missing 45-day window, **27:17**

THIRTY-MONTH STAY—Cont'd

NCE exclusivity, extending stay to
year 7.5, **27:26**
New stays, earning
generally, **27:18 to 27:23**
December 2003 rules, **27:20**
pop-up (newly issued) patents,
27:21
reformulation, **27:22**
repetitive stays under old rules,
27:19
working examples, **27:23**
Notifying FDA of lawsuit, **27:4**
Patentee delays, **27:9**
Pop-up (newly issued) patents,
effect of, **27:21**
Qualifying patents, **27:3**
Reformulation and new stay,
27:22
Reinstatement after wrongful
termination, **27:11**
Repetitive stays under old rules,
27:19
Shortening stay, **27:15**
Staggered expirations
generally, **27:24 to 27:27**
extending stay to year 7.5 after
NCE exclusivity, **27:26**
inter partes review, pending,
impact on stays, **27:27**
multiple applicants 30-month
stay, **27:24**
stay of court decision pending
appeal to maintain
30-month stay intact, **23:8,**
27:25
Stay not altered despite request,
27:16
Termination of stay
generally, **27:5 to 27:9**
appeal, generic company wins,
27:8
court decision, **27:6**
normal termination, **27:5**
patentee delays, **27:9**

INDEX

THIRTY-MONTH STAY—Cont'd

Termination of stay—Cont'd
reinstatement after wrongful
termination, **27:11**
staggered expirations, above
trial level, generic company
wins, **27:7**
Working examples, **27:23**

TYPES OF PATENTS

Pharmaceutical Patents, Common Types (this index)

UNENFORCEABILITY OF PATENT

Inequitable Conduct (this index)

USPTO

Fraud on Patent Office, **19:1**
Guidelines
obviousness, **7:23**
pharma patents, **5:6**
Utopian-world patent issuance in
USPTO, **6:10**

UTILITY

Subject Matter and Utility (this index)

VALIDITY AND INVALIDITY, FOUNDATIONS OF

Generally, **4:1 to 4:12**
Claim construction breadth and
invalidity, **4:2**
Prior Art (this index)

WAIVER

Paragraph IV Based 180-Day Exclusivity (this index)

WILLFUL INFRINGEMENT

Enhanced damages and willful
infringement. **Damages** (this index)

WRITTEN DESCRIPTION (§ 112)

Generally, **10:1 to 10:8**
Breaking chains of priority to
invalidate later patents, **10:9**
Broad claim construction leading
to written description invalidity, **10:6**
Genus and species, written
description support, **13:4**
Mechanics of written description
challenge, **10:7**
Negative limitations in claims and
specification support, **10:8**
Patent invalidity theories, **10:4**
Section 112(a) (pre-AIA § 112,
first paragraph), **10:2**
Specification
negative limitations in claims
and specification support,
10:8
ranges in specification, **10:5**
role of, **10:1**
When specification catalogs lists
of elements and claim plucks
out elements, **10:10**
Written description, generally,
10:3